Company

Slider

 

THE COMPANY

 
SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies.

SphingoTec GmbH was established in 2002 and is located in Hennigsdorf near Berlin, Germany. CEO Dr. Andreas Bergmann was one of the founders of B.R.A.H.M.S. AG. As former Chief Research Officer, he was responsible for the development of the “gold standard” sepsis biomarker Procalcitonin (B.R.A.H.M.S. PCT™).

 

MANAGEMENT

 

 

ADVISORY BOARD

 

 

EXECUTIVE TEAM

 

 

 

TEAM

 

  • Human Resources
    Anja Heindl
    HR Assistant
  • Intellectual Property
    Dr. Andrea Sparwaßer
    Patent and Project Manager
  • Finance
    Dajana Tandler
    Controller

 

  • Marketing
    Deborah Bergmann
    Head of Marketing & MSLM
  • Operations
    Marco Talke
    Lead of Cooperation and Supply
  • Sales
    Michał Bagrowski
    Senior Distribution Manager

 

  • Statistics
    Dr. Oliver Hartmann
    Head of Biostatistics
  • Marketing
    Ruxandra Lenz
    Sr Manager Marketing and Communications
  • Research and Development
    Dr. Tobias Hartmann
    Head of Product Development

 

CAREER

Our company is continually looking for highly motivated team members. If you are interested in joining our innovative team, please contact us at career@sphingotec.de or submit your application and CV HERE.

Top